Canndoc Reports Record Revenue Amid Cannabis Market Turmoil
Canndoc Reports Record Revenue Amid Cannabis Market Turmoil
InterCure Ltd. (NASDAQ:INCR) (TASE: INCR), which is doing business as Canndoc, reported its financial and operating results on Thursday for the three and six months ended June 30, 2023,
InterCure 有限公司。納斯達克股票代碼：INCR）（TASE：INCR），其業務是 坎多克，報告了 財務和經營業績 星期四在截至2023年6月30日的三個月和六個月中，
"The first half of 2023 is another solid performance for InterCure, with year-over-year revenue growing 14% and an adjusted EBITDA margin of 14%," InterCure CEO Alexander Rabinovitch said. "I am proud of our team's ability to execute despite some challenging market conditions when big players are exiting the space."
InterCure首席執行官表示：“2023年上半年是InterCure的又一次穩健表現，收入同比增長14％，調整後的息稅折舊攤銷前利潤率爲14％。” 亞歷山大·拉比諾維奇 說。“我爲我們的團隊的執行能力感到自豪，儘管市場條件充滿挑戰，但當大型企業退出該領域時，我們團隊的執行能力。”
1H 2023 Financial Highlights
2023 年上半年財務摘要
- Revenue totaled CA$75 million ($55.4 million), representing a year-over-year growth of 14%.
- Gross profit was CA$24 million or 33% of revenue, compared to CA$ 29.5 million in the prior year's period or 42% of the revenue.
- Operating profit was CA$4.2 million, down from CA$13.5 million in the same period of 2022.
- Adjusted EBITDA came in positive at CA$8.7 million, down from a CA$14.4 million adjusted EBITDA gain in the corresponding period of last year.
- Adjusted EBITDA margin was 14%, compared to 24% in the same period of 2022.
- As of June 30, the company had CA$299.67 million in total assets and CA$299.6 million in total liabilities and equity.
- 總收入爲7500萬加元（合5,540萬美元），同比增長14％。
- 毛利爲2400萬加元，佔收入的33％，而去年同期爲2950萬加元，佔收入的42％。
- 營業利潤爲420萬加元，低於2022年同期的1,350萬加元。
- 調整後的息稅折舊攤銷前利潤爲正數，爲870萬加元，低於去年同期調整後的息稅折舊攤銷前利潤增長1,440萬加元。
- 調整後的息稅折舊攤銷前利潤率爲14％，而2022年同期爲24％。
- 截至6月30日，該公司的總資產爲2.9967億加元，負債和權益總額爲2.996億加元。
Q2 2023 Financial Highlights
2023 年第二季度財務亮點
- Revenue totaled CA$36 million, representing an 8% year-over-year growth.
- Gross profit was CA$12 million or 32% of revenue.
- Seventh consecutive half-year growth representing an annualized revenue run rate of CA$149 million.
- CA$ 13 million in cash from operations.
- 總收入爲3,600萬加元，同比增長8％。
- 毛利爲1,200萬加元，佔收入的32％。
- 連續第七個半年增長，年化收入爲1.49億加元。
- 來自運營的現金爲1,300萬加元。
What's Next
下一步是什麼
"We continue to optimize our operations for continued growth supported by our leading position. We are encouraged by the new regulations in Israel and Germany as pharmaceutical cannabis becoming a world standard across Europe and many other territories," Rabinovitch continued, "We are also keeping an open eye on the U.S. Department of Health and Human Services scientific and medical evaluation, supporting cannabis to be classified as a Schedule III drug by the DEA and the opportunities it may generate to InterCure."
“在我們領先地位的支持下，我們將繼續優化運營，以實現持續增長。隨着藥用大麻在歐洲和許多其他地區成爲世界標準，以色列和德國的新法規令我們感到鼓舞。” 拉比諾維奇繼續說，“我們還對美國衛生與公共服務部的科學和醫學評估持開放態度，支持美國藥物管理局將大麻歸類爲附表三藥物，以及它可能爲InterCure帶來的機會。”
To learn more about how companies in the cannabis industry manage to stay afloat amid falling prices and a product glut, come join us at the Benzinga Cannabis Capital Conference, the place where deals get done.
要詳細了解大麻行業的公司如何在價格下跌和產品過剩的情況下設法維持生計，請加入我們的行列 Benzinga 大麻資本會議， 交易完成的地方。
The event is returning to Chicago this Sept 27-28 for its 17th edition.
該活動是 將於9月27日至28日重返芝加哥參加第17屆會議。
Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
立即獲取門票 在價格上漲之前，確保在大麻投資和品牌的中心佔有一席之地。
INCR Price Action
INCR 價格走勢
InterCure's shares traded 1.86% higher at $1.64 per share during the pre-market session on Friday morning.
InterCure's 股價上漲1.86％，至每股1.64美元 在週五上午的盤前交易時段。
Related News
相關新聞
- Medical Cannabis Company Better Is Suing InterCure For $35M
- InterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The Details
- InterCure Teams Up With TYSON 2.0 In Israel, Australia, United Kingdom, Germany And Other EU Countries
- 醫用大麻公司Better以3500萬美元起訴InterCure
- InterCure股票交易走低，第一季度收入增長22％，詳情如下
- InterCure 在以色列、澳大利亞、英國、德國和其他歐盟國家與 TYSON 2.0 合作
Photo: Courtesy of Emilio Takas on Unsplash
照片：由 Unsplash 上的 Emilio Takas 提供
譯文內容由第三人軟體翻譯。